Powered by

6-Month Data From the Surmodics Avess(TM) AV Fistula DCB First-in-Human Study Presented at VIVA 2020; Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months

Nov 09, 2020 - Business Wire

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS first-in-human (FIH) study of the company's Avess(TM) AV Fistula drug-coated balloon (DCB) was shared during a morning session at the Vascular Interventional Advances (VIVA) 2020 virtual conference.

The AVESS study is a prospective, multi-center, single-arm study to assess the safety and performance of the Ave...